Personalized Medicine Biomarkers Market By Product Type (Consumables, Instruments, Reagents), By Technology (Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers), By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Rare Diseases), By End-User (Hospitals, Diagnostic Laboratories, Research Institutes), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Personalized Medicine Biomarkers Market was valued at USD 4.1 billion in 2024-e and will surpass USD 6.9 billion by 2030; growing at a CAGR of 9.0% during 2025 - 2030.

The personalized medicine biomarkers market is experiencing rapid growth, driven by increasing demand for tailored healthcare solutions. Biomarkers play a crucial role in the field of personalized medicine by offering valuable insights into an individual’s genetic, proteomic, or metabolic profile. These insights enable healthcare providers to deliver treatments that are specifically tailored to the patient’s unique biological makeup, improving treatment outcomes and reducing adverse effects. As precision medicine continues to gain traction across various therapeutic areas, biomarkers are becoming indispensable tools in enhancing the efficacy of treatments and early detection of diseases.

Technological advancements in genomic, proteomic, metabolomic, and imaging biomarkers are significantly contributing to the market's expansion. These innovations allow for more precise identification and validation of biomarkers, further fueling their adoption across applications such as oncology, cardiovascular diseases, and neurological disorders. With growing investments in research and development, along with the increasing prevalence of chronic diseases, the personalized medicine biomarkers market is expected to continue its upward trajectory, becoming an integral part of modern healthcare.

Reagents Product Type is Largest Owing to Essential Role in Biomarker Detection

Reagents are the largest product type in the personalized medicine biomarkers market owing to their essential role in biomarker detection and analysis. Reagents, such as antibodies, enzymes, and other chemical compounds, are crucial for the identification and quantification of biomarkers in biological samples. They are used extensively in various laboratory procedures, including genomic, proteomic, and metabolomic profiling, to detect disease-related biomarkers and monitor patient response to treatment.

The increasing demand for personalized medicine, particularly in oncology and other chronic conditions, has fueled the need for high-quality reagents that ensure accurate and reliable biomarker detection. Reagents are often used in conjunction with advanced technologies like next-generation sequencing (NGS) and mass spectrometry, making them a critical component of the biomarker discovery and validation process. As precision medicine continues to gain momentum, the reagents segment is expected to maintain its leadership position in the personalized medicine biomarkers market.

Personalized Medicine Biomarkers Market Size

Genomic Biomarkers Technology is Largest Owing to Strong Clinical Applications

Genomic biomarkers are the largest technology segment in the personalized medicine biomarkers market owing to their strong clinical applications in diagnosing and treating a wide range of diseases. Genomic biomarkers involve the analysis of genetic material, such as DNA and RNA, to identify genetic mutations or variations that are associated with specific diseases, including cancer and genetic disorders. These biomarkers are increasingly being used in precision oncology, where they guide treatment decisions by identifying mutations that may respond to targeted therapies.

The growth of the genomic biomarkers segment is further supported by the widespread adoption of next-generation sequencing (NGS) technologies, which allow for comprehensive and cost-effective genetic profiling. Genomic biomarkers also play a significant role in pharmacogenomics, where they help predict how patients will respond to specific drugs based on their genetic makeup. As the understanding of the human genome continues to evolve, genomic biomarkers will remain a central component of personalized medicine, driving their dominance in the market.

Oncology Application is Largest Owing to High Demand for Targeted Therapies

Oncology is the largest application segment in the personalized medicine biomarkers market, driven by the high demand for targeted therapies and the growing prevalence of cancer worldwide. Cancer treatment has evolved significantly with the advent of personalized medicine, as biomarkers are increasingly used to identify specific mutations in cancer cells that can be targeted by precision therapies. By analyzing genetic, proteomic, and metabolomic profiles, biomarkers can help tailor treatment regimens that are more effective and less toxic than traditional chemotherapy.

The oncology segment is expected to continue to dominate the market, as personalized therapies are becoming the standard of care for many cancer types. Advances in liquid biopsy technologies, which allow for the detection of cancer-related biomarkers in blood samples, are further boosting the adoption of personalized biomarkers in oncology. With ongoing research and development in this field, the oncology application is set to drive continued growth in the personalized medicine biomarkers market.

Diagnostic Laboratories End-User is Fastest Growing Owing to Expansion of Testing Services

Diagnostic laboratories are the fastest-growing end-user segment in the personalized medicine biomarkers market, owing to the rapid expansion of testing services and the increasing demand for personalized health assessments. Diagnostic laboratories play a crucial role in the biomarker detection process, offering specialized testing services to identify genetic, proteomic, and metabolomic biomarkers associated with various diseases. These laboratories are equipped with state-of-the-art technologies, such as mass spectrometry and NGS platforms, to deliver high-quality and accurate results.

The growth of this segment is further driven by the rising adoption of genetic testing and biomarker-based diagnostics in clinical settings, particularly in oncology, cardiovascular diseases, and neurological disorders. As healthcare providers increasingly rely on diagnostic laboratories to obtain personalized insights for treatment planning, the diagnostic laboratories segment is expected to continue to expand rapidly. Additionally, the growing number of direct-to-consumer genetic testing services offered by diagnostic labs is further contributing to the segment’s growth.

North America Region is Largest Owing to Advanced Healthcare Infrastructure and R&D Investment

North America is the largest region in the personalized medicine biomarkers market, owing to its advanced healthcare infrastructure, robust research and development capabilities, and high adoption rate of personalized medicine technologies. The United States, in particular, leads in biomarker research and clinical applications, with many biotechnology and pharmaceutical companies based in the region driving innovations in biomarker discovery and validation. Additionally, the presence of well-established healthcare institutions, academic research centers, and diagnostic laboratories further supports the growth of the market.

The region's regulatory environment, which supports the approval and commercialization of new biomarkers and diagnostic tests, also contributes to its dominance in the market. As personalized medicine continues to evolve, North America is expected to maintain its leadership position, with ongoing advancements in biomarker-based diagnostics and therapies.

Personalized Medicine Biomarkers Market Size by Region 2030

Leading Companies and Competitive Landscape

Leading companies in the personalized medicine biomarkers market include Roche, Abbott Laboratories, Thermo Fisher Scientific, and Illumina, which are at the forefront of biomarker discovery, diagnostics, and personalized treatment solutions. These companies are heavily involved in the development of innovative products, including reagents, instruments, and testing platforms, to support biomarker-based personalized medicine. They also play a significant role in the commercialization of precision oncology therapies, leveraging biomarker insights to improve treatment outcomes.

The competitive landscape is characterized by significant investments in research and development, as companies strive to identify new biomarkers and technologies that can enhance the effectiveness of personalized medicine. Collaborations between pharmaceutical companies, biotechnology firms, and research institutions are common, as stakeholders work together to discover and validate biomarkers for a wide range of diseases. As the market for personalized medicine continues to expand, the competitive environment will intensify, with both established players and new entrants contributing to innovations in the field.

Recent Developments:

  • In December 2024, Thermo Fisher Scientific launched a new proteomic biomarker discovery platform for precision oncology.
  • In November 2024, Roche Diagnostics announced the approval of a new liquid biopsy test for early cancer detection, leveraging genomic biomarkers.
  • In October 2024, Guardant Health expanded its biomarker-based testing portfolio with a new test for personalized cancer treatment planning.
  • In September 2024, Illumina, Inc. introduced a new sequencing technology aimed at accelerating the discovery of personalized biomarkers for rare diseases.
  • In August 2024, Bio-Rad Laboratories launched a proteomic biomarker assay to support precision medicine in neurological disorders.

List of Leading Companies:

  • Thermo Fisher Scientific
  • Roche Diagnostics
  • Abbott Laboratories
  • Qiagen
  • Bio-Rad Laboratories
  • PerkinElmer, Inc.
  • Agilent Technologies
  • Illumina, Inc.
  • Myriad Genetics
  • Guardant Health
  • Genomic Health
  • Siemens Healthineers
  • Becton Dickinson and Company
  • Exact Sciences
  • Foundation Medicine

Report Scope:

Report Features

Description

Market Size (2024-e)

USD 4.1 billion

Forecasted Value (2030)

USD 6.9 billion

CAGR (2025 – 2030)

9.0%

Base Year for Estimation

2024-e

Historic Year

2023

Forecast Period

2025 – 2030

Report Coverage

Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments

Segments Covered

Personalized Medicine Biomarkers Market By Product Type (Consumables, Instruments, Reagents), By Technology (Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers), By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Rare Diseases), By End-User (Hospitals, Diagnostic Laboratories, Research Institutes)

Regional Analysis

North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa)

Major Companies

Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Qiagen, Bio-Rad Laboratories, PerkinElmer, Inc., Agilent Technologies, Illumina, Inc., Myriad Genetics, Guardant Health, Genomic Health, Siemens Healthineers, Becton Dickinson and Company, Exact Sciences, Foundation Medicine

Customization Scope

Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements

1. Introduction

   1.1. Market Definition

   1.2. Scope of the Study

   1.3. Research Assumptions

   1.4. Study Limitations

2. Research Methodology

   2.1. Research Approach

      2.1.1. Top-Down Method

      2.1.2. Bottom-Up Method

      2.1.3. Factor Impact Analysis

  2.2. Insights & Data Collection Process

      2.2.1. Secondary Research

      2.2.2. Primary Research

   2.3. Data Mining Process

      2.3.1. Data Analysis

      2.3.2. Data Validation and Revalidation

      2.3.3. Data Triangulation

3. Executive Summary

   3.1. Major Markets & Segments

   3.2. Highest Growing Regions and Respective Countries

   3.3. Impact of Growth Drivers & Inhibitors

   3.4. Regulatory Overview by Country

4. Personalized Medicine Biomarkers Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030)

   4.1. Consumables

   4.2. Instruments

   4.3. Reagents

5. Personalized Medicine Biomarkers Market, by Technology (Market Size & Forecast: USD Million, 2023 – 2030)

   5.1. Genomic Biomarkers

   5.2. Proteomic Biomarkers

   5.3. Metabolomic Biomarkers

   5.4. Imaging Biomarkers

6. Personalized Medicine Biomarkers Market, by Application (Market Size & Forecast: USD Million, 2023 – 2030)

   6.1. Oncology

   6.2. Cardiovascular Diseases

   6.3. Neurological Disorders

   6.4. Rare Diseases

7. Personalized Medicine Biomarkers Market, by End-User (Market Size & Forecast: USD Million, 2023 – 2030)

   7.1. Hospitals

   7.2. Diagnostic Laboratories

   7.3. Research Institutes

8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030)

   8.1. Regional Overview

   8.2. North America

      8.2.1. Regional Trends & Growth Drivers

      8.2.2. Barriers & Challenges

      8.2.3. Opportunities

      8.2.4. Factor Impact Analysis

      8.2.5. Technology Trends

      8.2.6. North America Personalized Medicine Biomarkers Market, by Product Type

      8.2.7. North America Personalized Medicine Biomarkers Market, by Technology

      8.2.8. North America Personalized Medicine Biomarkers Market, by Application

      8.2.9. North America Personalized Medicine Biomarkers Market, by End-User

      8.2.10. By Country

         8.2.10.1. US

               8.2.10.1.1. US Personalized Medicine Biomarkers Market, by Product Type

               8.2.10.1.2. US Personalized Medicine Biomarkers Market, by Technology

               8.2.10.1.3. US Personalized Medicine Biomarkers Market, by Application

               8.2.10.1.4. US Personalized Medicine Biomarkers Market, by End-User

         8.2.10.2. Canada

         8.2.10.3. Mexico

    *Similar segmentation will be provided for each region and country

   8.3. Europe

   8.4. Asia-Pacific

   8.5. Latin America

   8.6. Middle East & Africa

9. Competitive Landscape

   9.1. Overview of the Key Players

   9.2. Competitive Ecosystem

      9.2.1. Level of Fragmentation

      9.2.2. Market Consolidation

      9.2.3. Product Innovation

   9.3. Company Share Analysis

   9.4. Company Benchmarking Matrix

      9.4.1. Strategic Overview

      9.4.2. Product Innovations

   9.5. Start-up Ecosystem

   9.6. Strategic Competitive Insights/ Customer Imperatives

   9.7. ESG Matrix/ Sustainability Matrix

   9.8. Manufacturing Network

      9.8.1. Locations

      9.8.2. Supply Chain and Logistics

      9.8.3. Product Flexibility/Customization

      9.8.4. Digital Transformation and Connectivity

      9.8.5. Environmental and Regulatory Compliance

   9.9. Technology Readiness Level Matrix

   9.10. Technology Maturity Curve

   9.11. Buying Criteria

10. Company Profiles

   10.1. Thermo Fisher Scientific

      10.1.1. Company Overview

      10.1.2. Company Financials

      10.1.3. Product/Service Portfolio

      10.1.4. Recent Developments

      10.1.5. IMR Analysis

    *Similar information will be provided for other companies 

   10.2. Roche Diagnostics

   10.3. Abbott Laboratories

   10.4. Qiagen

   10.5. Bio-Rad Laboratories

   10.6. PerkinElmer, Inc.

   10.7. Agilent Technologies

   10.8. Illumina, Inc.

   10.9. Myriad Genetics

   10.10. Guardant Health

   10.11. Genomic Health

   10.12. Siemens Healthineers

   10.13. Becton Dickinson and Company

   10.14. Exact Sciences

   10.15. Foundation Medicine

11. Appendix

A comprehensive market research approach was employed to gather and analyze data on the Personalized Medicine Biomarkers Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Personalized Medicine Biomarkers Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.

Research Approach -

Secondary Research

Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.

Primary Research

Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:

  • Validating findings and assumptions derived from secondary research
  • Gathering qualitative and quantitative data on market trends, drivers, and challenges
  • Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
  • Assessing the supply-side landscape, including technological advancements and recent developments

Market Size Assessment

A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Personalized Medicine Biomarkers Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:

  1. Identification of key industry players and relevant revenues through extensive secondary research
  2. Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
  3. Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources

Bottom Up and Top Down -

Data Triangulation

To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.

NA

Please state your requirements.


I have read the Terms & Conditions and Privacy Policy. I agree to its terms.

Report Buying Options